Replimune (REPL) EBT (2017 - 2026)

Replimune (REPL) has 10 years of EBT data on file, last reported at -$73.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 1.05% year-over-year to -$73.5 million; the trailing twelve-month figure through Mar 2026 stood at -$396.3 million (down 60.57% YoY), and the FY2026 full-year result was -$314.5 million, down 27.41% from the prior year.
• EBT retreated to -$73.5 million in Q1 2026, from -$71.2 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$31.6 million in Q1 2022 to a low of -$128.7 million in Q2 2025.
• A 5-year average of -$62.6 million and a median of -$53.8 million in 2024 frame the typical range for EBT.
• Across the five-year window, EBT soared 51.52% in 2022 and slumped 139.39% in 2025, its largest moves.
• Tracing REPL's EBT over 5 years: stood at -$39.7 million in 2022, then declined by 27.61% to -$50.6 million in 2023, then dropped by 29.85% to -$65.8 million in 2024, then dropped by 8.33% to -$71.2 million in 2025, then declined by 3.11% to -$73.5 million in 2026.
• Business Quant data shows REPL's EBT at -$73.5 million in Q1 2026, -$71.2 million in Q4 2025, and -$122.9 million in Q3 2025.